iStock.com/Fly View Productions
Interest in mRNA vaccines has surged in recent years, largely due to the success and widespread attention of COVID-19 vaccines using this technology. The speed of their development, the robust protection they provide, and their favorable safety profiles have demonstrated the wide-ranging potential of mRNA technology. However, the potential of mRNA goes far beyond infectious diseases. In oncology, mRNA vaccines are being explored as a personalized therapeutic strategy that trains a patient’s immune system to recognize tumor-specific mutations. This targeted strategy harnesses the body’s natural defenses to fight cancer cells while sparing healthy tissue, offering a promising complement to existing therapies. As oncology nurses, understanding the principles behind mRNA vaccines and their role in immunotherapy is increasingly important, as these treatments hopefully move from clinical trials to routine care.
A Phase 1 Study of a Personalized mRNA Vaccine in TNBC
A recent phase 1 trial published in Nature by Ugur Sahin, MD, and colleagues explored the safety, feasibility, and immune-activating potential of a personalized uridine mRNA-based neoantigen vaccine in patients with triple-negative breast cancer (TNBC) following standard therapy, including surgery with or without chemotherapy and radiotherapy. Fourteen patients received a vaccine designed to target unique mutations in their own tumors, identified through detailed DNA and RNA sequencing. These patient-specific mutations, called neoantigens, were converted into RNA fragments and packaged into lipid nanoparticles for intravenous delivery. This delivery system ensures that the immune system efficiently takes up the neoantigens and mounts a targeted response.
The vaccine was generally well tolerated, with no severe or unexpected adverse events reported. Its RNA–lipoplex formulation was specifically designed to deliver the neoantigens to immune cells, teaching the body to recognize and attack tumor cells while sparing healthy tissue. In practical terms, this means that the patient’s own immune system is trained to detect subtle, tumor-specific changes and respond aggressively against them.
Analysis of immune responses showed that nearly all patients developed strong T cell activity against the selected neoantigens. Both CD8+ cytotoxic T cells, which can directly kill cancer cells, and CD4+ helper T cells, which support and sustain the immune response, were activated. Many patients mounted responses against multiple antigens at once, demonstrating a broad immune response. Importantly, these neoantigen-specific T cells persisted years after vaccination and included a mix of late-differentiated cytotoxic effector cells, ready to attack tumor cells immediately, and stem-like memory T cells, capable of self-renewal and long-term immune surveillance. Some patients developed entirely new T cell responses after vaccination, while others showed amplification of pre-existing immune responses. Special laboratory techniques allowed researchers to track these T cells in the blood over time and confirm that they recognized the patient’s tumor mutations.
Clinical outcomes were encouraging. At a median follow-up of five years, ten of the 14 patients remained relapse-free. Three patients experienced disease recurrence, each illustrating a different way tumors can evade the immune system. One patient with BRCA1-mutated bilateral tumors developed an independent tumor not targeted by the vaccine. Another had low initial major histocompatibility complex (MHC) class I expression, and the recurrent tumor lost MHC class I, preventing T cells from recognizing it. The third patient had a weak initial vaccine-induced response but later responded to anti-PD-1 therapy before ultimately relapsing.
This study demonstrates that even in cancers with a moderate mutation load like TNBC, neoantigen vaccines can generate durable and multi-targeted T cell responses. Tumors may evade immune attack through a lack of initial response, loss of antigen presentation, or development of independent tumor clones. These findings suggest that combining neoantigen vaccines with other therapies may be necessary for certain patients.
Nursing Considerations
For oncology nurses, these results highlight the importance of understanding how personalized cancer vaccines work. Nurses play a critical role in monitoring for vaccine-related side effects, such as mild flu-like symptoms, injection site reactions, or transient fever, and providing guidance on symptom management. Educating patients on what to expect from immune responses is essential. For example, explaining that a temporary increase in fatigue or low-grade fever may reflect the activation of T cells rather than infection. Nurses also support long-term follow-up care, including coordinating blood draws to track immune responses and helping patients understand the significance of immune persistence over months or years.
Knowing that these vaccines can generate lasting immunity equips nurses to guide patients through complex treatment plans, such as combining neoantigen vaccines with checkpoint inhibitors. Nurses can also encourage eligible patients to consider participation in clinical trials, where patients may receive a personalized mRNA vaccine designed to target mutations unique to their tumors. By framing these opportunities with concrete examples of potential benefits and side effects, nurses help patients make informed decisions.
